Delphi consensus on the real-world application of the updated diagnostic and treatment guidelines for migraine in Asia Pacific - Takeaways - MDSpire

Delphi consensus on the real-world application of the updated diagnostic and treatment guidelines for migraine in Asia Pacific

  • By

  • Charles Hua Chiang Siow

  • Shengyuan Yu

  • Surat Tanprawate

  • Shuu-Jiun Wang

  • Elspeth J. Hutton

  • Byung-Kun Kim

  • Min Kyung Chu

  • Norihiro Suzuki

  • Wanakorn Rattanawong

  • Ka Sing Wong

  • Mi Ji Lee

  • Zhao Dong

  • Hebo Wang

  • Xianliang Li

  • Koichi Hirata

  • Takao Takeshima

  • May 28, 2026

  • 0 min

Share

  • 1

    The Delphi consensus involved 14 headache specialists from seven Asia-Pacific countries to improve migraine diagnosis and management.

  • 2

    Consensus was achieved on 12 of 21 statements, with 93% using ICHD-3 criteria for migraine diagnosis.

  • 3

    Anti-CGRP mAbs were deemed effective by 86% of participants, addressing unmet needs in migraine prevention.

  • 4

    Efficacy, safety, and tolerability were the primary factors influencing the selection of anti-CGRP mAbs.

  • 5

    Participants advised against using anti-CGRP mAbs in children under 12 due to insufficient evidence.

Original Source(s)

Delphi consensus on the real-world application of the updated diagnostic and treatment guidelines for migraine in Asia Pacific

  • by Charles Hua Chiang Siow, Shengyuan Yu, Surat Tanprawate, Shuu-Jiun Wang, Elspeth J. Hutton, Byung-Kun Kim, Min Kyung Chu, Norihiro Suzuki, Wanakorn Rattanawong, Ka Sing Wong, Mi Ji Lee, Zhao Dong, Hebo Wang, Xianliang Li, Koichi Hirata, Takao Takeshima

  • May 28, 2026

Related Content

Development and validation of a digital tool to aid in migraine diagnosis

Floaters May Signal Higher Risk Than Flashes

New study examines retinal detachment risk in primary care presentations

Who Decides When a Doctor Steps Back?

Cognitive decline, credentialing, and why “I’ll know” often isn’t enough.